So there was a conference call hosted by Auris Medical which I attended today at 14:00 o'clock (European time).
I don't have the slides in front of me - and - I do not know if they will be released, so the following is from memory (and may not be 100% accurate, therefore):
- Two subgroups within the study population have been identified for which efficacy of AM-101 was demonstrated: those suffering from otitis media (16%) and those suffering from severe tinnitus (30%).
- The overall subgroup constituting of traumatic injury (i.e. mainly/only noise induced, I believe), and which accounts for 84% of the participants in the trial, did not show a statistically meaningful difference (vs. placebo).
- 120 extra patients will be enrolled in the European trial (i.e. 60 patients allocated to stratum A + B, respectively). This is the reason for the extension of the timeline of "early 2018" before final results will be available (due regulatory paperwork + execution of the trial itself).
- High degree of variability in terms of patients experiencing positive outcomes was seen depending on the treatment centres.
- The TFI-score showed a better improvement than the TLQ score (tinnitus loudness questionnaire). It is believed - based on physician feedback - that, a daily rating of tinnitus loudness over an 84-day period made an improvement difficult to establish for patients.
The 120 extra patients will increase the statistical power of the clinical trial in order to prove/disprove efficacy (hopefully the former).